PMID- 27768213
OWN - NLM
STAT- MEDLINE
DCOM- 20170803
LR  - 20171213
IS  - 1724-6075 (Electronic)
IS  - 0391-5603 (Linking)
VI  - 83
IP  - Suppl 2
DP  - 2016 Oct 4
TI  - Radiofrequency-induced thermo-chemotherapy effect (RITE) for non muscle invasive 
      bladder cancer treatment: current role and perspectives.
PG  - 7-17
LID - 10.5301/uro.5000197 [doi]
AB  - OBJECTIVE: An updated review of intravesical radiofrequency (RF)-induced 
      thermo-chemotherapy effect (RITE) for NMIBC with regard to efficacy, adverse 
      events (AEs) and perspectives. EVIDENCE ACQUISITION: An extensive and sensitive 
      search for RF-induced chemo-hyperthermia in Medline, Embase, Cochrane and 
      ClinicalTrials.gov databases was performed. A table of published clinical trials 
      up to 2016 was constructed. No meta-analysis could be performed on the basis of 
      new papers. EVIDENCE SYNTHESIS: Recurrence was seen 59% less after RITE than 
      after mitomycin C (MMC) alone in adjuvant clinical setting with an overall 
      bladder preservation rate after RITE of 85%. The efficacy was proved to be 
      comparable to that of Bacillus Calmette-Guerin (BCG), based on a single 
      comparative multicentric study. Due to short follow-up, no conclusions can be 
      drawn about time to recurrence and progression. The AE rate in RITE was higher, 
      although not statistically significant, than MMC alone and similar to that of 
      BCG, albeit different in the type of AE. In almost all studies, no severe AEs are 
      reported. CONCLUSIONS: RITE appears as a promising treatment option for NMIBC, 
      particularly for high-risk patients with recurrent tumors, for those unsuitable 
      for radical cystectomy and when Bacillus Calmette-Guerin treatment is 
      contraindicated. Further high-level evidence is needed for both reliable and 
      reproducible data on efficacy and adverse events.
FAU - Colombo, Renzo
AU  - Colombo R
AD  - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI, Milan - 
      Italy.
FAU - van Valenberg, Hans
AU  - van Valenberg H
AD  - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen - The 
      Netherlands.
FAU - Moschini, Marco
AU  - Moschini M
AD  - Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, URI, Milan - 
      Italy.
AD  - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 
      Vienna General Hospital, Vienna - Austria.
FAU - Witjes, Johannes A
AU  - Witjes JA
AD  - Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen - The 
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161001
PL  - United States
TA  - Urologia
JT  - Urologia
JID - 0417372
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 50SG953SK6 (Mitomycin)
SB  - IM
MH  - Antibiotics, Antineoplastic/*administration & dosage
MH  - Humans
MH  - Hyperthermia, Induced
MH  - Mitomycin/*administration & dosage
MH  - Neoplasm Invasiveness
MH  - Urinary Bladder Neoplasms/*drug therapy/pathology
EDAT- 2016/10/22 06:00
MHDA- 2017/08/05 06:00
CRDT- 2016/10/22 06:00
PHST- 2016/09/05 00:00 [accepted]
PHST- 2016/10/22 06:00 [pubmed]
PHST- 2017/08/05 06:00 [medline]
PHST- 2016/10/22 06:00 [entrez]
AID - AB5467B2-E759-4AFC-A691-9A3B4047E3ED [pii]
AID - 10.5301/uro.5000197 [doi]
PST - ppublish
SO  - Urologia. 2016 Oct 4;83(Suppl 2):7-17. doi: 10.5301/uro.5000197. Epub 2016 Oct 1.